In conclusion, BM-MSCs/IFN-are effective in inhibiting neoplastic plasma cell growth; however, systemic administration of engineered MSCs still needs to be improved to make this approach potentially suitable for the treatment of multiple myeloma. 
INTRODUCTION
Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematological cancers [1] . Despite the fact that standard chemotherapy is usually effective in lowering the disease burden, complete remission is achievable only in a minority of patients, and responses are rarely persistent [2] . Several randomized studies have shown the improvement of both disease-free and overall survival by using autologous hematopoietic stem cell transplantation as compared with standard chemotherapy [3, 4] . However, this approach is not curative, because of the persistence and ultimate recurrence of chemotherapy-resistant disease. Recent studies based on the use of biological agents, such as thalidomide, lenalidomide or bortezomib, expecially when used in combination with dexamethasone, have shown that a significantly higher number of patients may achieve clinical major responses [5, 6] . Allogeneic hematopoietic stem cell transplantation is curative for a small subset of patients developing graft-versus-myeloma effect, but it is associated with significant morbidity and mortality as a consequence of the regimen-related toxicity and because of infections and tissue injury due to graft-versus-host disease (GvHD). Thus, MM still remains an uncurable disease [7] . The treatment of MM with interferon-alpha (IFN-) has been used for years as maintenance therapy, as it may prolong survival by delaying tumor progression [8] .
Mesenchymal stromal cells (MSCs) are non-hematopoietic progenitor cells endowed with multilineage differentiation potential into various cell types, including fibroblasts, adipocytes, osteoblasts, chondrocytes, skeletal and cardiac myocytes and, under specific experimental conditions, neural cells [9] . MSCs have powerful regulatory properties towards practically all immune effectors, including T, B, NK and dendritic cells, and they can modulate in vivo autoreactive immune responses, such as GvHD [10] . MSCs may also support tumor development, as they inhibit the specific immunity against neoplastic cells [11, 12] . Studies in rodents show an initial broad bio-distribution of systemically infused MSCs, followed by a small capacity of longterm engraftment [13] . However, they may survive and proliferate in the presence of cycling neoplastic cells, and are incorporated in tumors as stromal fibroblasts [14] , thus competing with the local mesenchymal cell precursors [15] . At the same time, they are capable of promoting metastatic dissemination of primary tumors in some animal models [16] .
MSCs can be a suitable tool for gene therapy strategies [17] . In fact, they can be genetically engineered with genes encoding for active molecules that can target specifically cancer cell proliferation, reduce MSC immune regulatory properties and eventually enhance the anti-tumor immune response. MSC transduction with cDNAs coding for factors with anti-tumor activity, such as IFN-and -, may represent a promising approach for cancer treatment [14, 18] .
In our study, we transduced mouse bone marrow derived MSCs (BM-MSCs) with IFN-cDNA (BM-MSCs/IFN-) and we analyzed their effects in vivo in the Sp6 plasmacytoma mouse model, which can be either hampered by the onset of specific immune response [19] or favoured by the injection of BM-MSCs [12] . 
MATERIALS AND METHODS

Cell lines
Sp6 hybridoma cells, derived from the P3/X63-Ag8 mouse plasmacytoma [20] , were used for in vitro and in vivo experiments in mouse. Sp6 is a Balb/c mouse plasmacytoma induced by mineral oil and displaying prevalent peritoneal localization [21] , although it can also ultimately localize into the bone-marrow (BM) after parenchymal dissemination (SS, personal observation), when injected intravenously (i.v.), as described for mouse S107 e X24 plasmacytomas [22] . Sp6 cells are highly tumorigenic when injected subcutaneously (s.c.) in syngeneic Balb/c mouse strain [20] and their growth is favored in vivo by the presence of MSCs of different sources [12] . Sp6 cells were grown in vitro in RPMI 1640 (Gibco Invitrogen Corporation, San Diego, CA, USA) supplemented with 10% fetal bovine serum (FBS; Euroclone, Pavia, Italy) and 5% L-glutamine (Biochrom AG, Berlin, Germany).
Mouse BM-MSCs were obtained from 7-10 week-old Balb/c (Balb/cByJIco, Charles River Italia, Calco, LC, Italy), as previously described [12, [23] [24] [25] .
The 293T human kidney cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and grown in DMEM supplemented with 10% FBS. 293T cells were used both as vector packaging cells and for titration experiments.
Plasmids
The human immunodeficiency virus type 1 (HIV-1)-derived lentiviral vectors used in this study were generated by exploiting the transient three-plasmid vector-packaging system based on 293T cells, as previously described [26] . The construct pRRL-SIN18-cPPT-insert-PRE, expressing either the enhanced green fluorescent protein (EGFP) or the murine IFN-gene from an internal cytomegalovirus (CMV) promoter, was used as transfer vector [27] . The genomic RNA was packaged in lentiviral particles produced by transfection of pCMV R8.74, a plasmid carrying the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Immunofluorescence analysis and monoclonal antibodies
Cells were analyzed by immunofluorescence and flow cytometry (FACScalibur, Becton DickinsonPharmigen, Milan, Italy). Sp6 cells were analyzed as previously described [19] . total doses (n=15). All s.c. injections were performed in the same anatomical quarter (usually within a radius of 0.5 cm around the first inoculum), as previously described [19] . In order to test in vivo engraftment of BM-MSCs inside Sp6 tumor, a subgroup of mice was injected s.c. simultaneously Axiovision™.
Co-culture experiment and evaluation of apoptosis in vitro
In vivo experiments
Morphometry
Tumor sections of 5-8 μm were processed for immunohistochemistry by standard procedures.
Tumor vessels were labeled using immunofluorescent staining for vWF and -SMA. Negative IFN-production by BM-MSCs and BM-MSCs/IFN-was evaluated by ELISA in culture supernatants (n=3). In the case of BM-MSCs, the levels of IFN-were below the detection limit of the assay (12.5 pg/ml) in all samples, whereas IFN-level in the supernatants of BM-MSCs/IFN-, tested in the same conditions, was 1270.86 ± 308.69 pg/ml. Repeated sampling after four weeks of culture showed equivalent levels of IFN-. On the other hand, the level of IFN-in the supernatants of Sp6/IFN-cells was 1803.91±400.83 pg/ml." Figure 1) .
BM-MSCs/IFN-inhibit the survival of Sp6 cells in vitro
In vitro, BM-MSCs/IFN-inhibit the survival of Sp6 cells, either in direct contact and in Transwell TM conditions (Figure 1) . (Figure 2) . We further tested the dissemination of both cell types in samples taken from the spleen, the liver, the central nervous system and lungs upon either s.c. or i.v. showed a significant delay in the onset of palpable tumors and a trend towards slower tumor growth, thus resulting in prolonged EFS (P<0.001) and better overall survival (OS) (P<0.001) (Figure 3) . In fact, median EFS was 17 days in mice treated with one single dose of BM- (Figure 3 ). We then analyzed the tumor vasculature using a double staining for vWF and -SMA to identify endothelial and perivascular cells. Complex vasculo-stromal axis were evident only in untreated mice ( Figure 4I and L) Complete statistical evaluation is reported in Table 1 Myeloma is a systemic and multifocal disease that develops inside the BM. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
BM-MSCs/IFN-alter tumor architecture
ACKNOWLEDGEMENTS
No competing financial interests exist.
We thank Nadia Brutti for her excellent technical support. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w Stem Cells and Development   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
